Recent progress in gene therapy for cystic fibrosis
Related Experiment Video
Updated: Aug 15, 2026

A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model
Published on: October 31, 2012
1Department of Gene Therapy, Imperial College School of Medicine, National Heart & Lung Institute, London, UK. u.griesenbach@ic.ac.uk
Abstract:
Cystic fibrosis (CF) is a monogenic disorder and is therefore a good candidate for gene therapy. Initial clinical trials provided proof-of-principle for gene transfer to the airways, but efficiency was low and likely to be insufficient for clinical benefit. Here, we review the progress in CF gene therapy over the last 12 months, including recent advances in viral and non-viral gene transfer agents and novel strategies, such as RNA repair and stem cell gene therapy.
Related Concept Videos
What is Genetic Engineering?
Gene Therapy
CRISPR
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Pharmacogenomics: Identification of New Drug Targets
Microorganisms in Medicine and Therapeutics

